evipedia.ai
← Back

Intermittent Hypoxia-Hyperoxia for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Intermittent hypoxia-hyperoxia is a machine-delivered breathing course alternating short spells of low-oxygen air with oxygen-rich recovery, used as a brief, controlled stress to improve heart and metabolic health. Lower resting blood pressure is its best-supported benefit; other gains rest on few, small studies, mostly in older patients rather than well people. Recorded harms are mild and short-lived, but its deliberate oxygen drops make screening and supervision matter. (Full Review)

Protocol

Standard course (rest protocol)
15 sessions of 45 minutes
Five days a week for three weeks, breathing through a face mask while seated; 4–8 hypoxic-hyperoxic cycles per session
Hypoxic phase
10–14% oxygen, 1–5 minutes
Individually set from the hypoxic pre-test (10 minutes of 12% oxygen)
Hyperoxic phase
30–40% oxygen, 1–3 minutes
Continued until saturation recovers; the device switches phases on measured saturation
Time to effect
Blood pressure
3–6 weeks
Measured after full courses; nothing meaningful is assessable from one or two sessions
Liver fat and liver enzymes
3 weeks
Fell below sham across a three-week course in metabolic syndrome
Fasting and post-load glucose
3 weeks
Fell after fifteen sessions; still lower one month after the course

Benefits

Contraindications
  • Demonstrated intolerance on the pre-exposure hypoxic test, or resting arterial oxygen saturation below 93%
  • Unstable angina (Canadian Cardiovascular Society class 3–4), severe heart failure (New York Heart Association class III–IV), or significant arrhythmia
  • Acute coronary syndrome within the preceding 4 weeks
  • Chronic obstructive pulmonary disease, pulmonary fibrosis, or any need for continuous or intermittent oxygen or ventilation
  • Untreated hypertension, or untreated and uncontrolled diabetes
  • Liver cirrhosis of Child-Pugh class C, or chronic kidney disease with estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Pregnancy, active cancer, or acute inflammatory illness
  • Severe cognitive impairment that prevents mask use or symptom reporting (mini-mental state examination score below 7)
    •
Key Interactions
  • Carbonic anhydrase inhibitors (acetazolamide): shift each hypoxic phase from its dosing pre-test; pre-test repeated after starting or stopping
  • Beta-blockers (carvedilol, metoprolol): mislead heart-rate-based dosing; pre-test repeated after any dose change
  • Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): tended to shift the saturation trajectory; pre-test repeated after starting
  • Opioids and sedatives (morphine, benzodiazepines): pairing avoided (theoretical); deeper, slower-to-reverse hypoxic phases
  • Over-the-counter sedating medicines (diphenhydramine, doxylamine): (theoretical) may blunt breathing responses; kept away from session times
  • Antioxidant supplements (high-dose vitamin C and vitamin E): (theoretical) high doses around sessions could blunt the redox signal
  • Dietary nitrate (beetroot juice, nitrate salts): additive effect; may raise tolerance of hypoxic phases and blunt the stimulus; intake separated from session days
  • Supplemental oxygen and non-invasive ventilation: concurrent use avoided (theoretical)
  • Other interventions — hyperbaric oxygen and altitude exposure: separated (theoretical); same-day stacking makes the dose unquantifiable
    •

Risk & Side Effects

  • High: Deep arterial oxygen desaturation during each hypoxic phase
    •
  • Medium: Altitude-type symptoms during early sessions
    •
  • Low: Transient rise in LDL cholesterol immediately after a session; cerebral oxygen desaturation; transient fast heart rate and cardiovascular strain; harm from excessive low-oxygen dose
    •
  • Speculative: Pro-oxidant and inflammatory marker shifts; unsupervised use without cardiopulmonary screening
    •

Monitoring

Marker Target Why
Hypoxic pre-test Not specified in the ER Screens for intolerance and sets the protocol
Lowest arterial oxygen saturation during a session Not below 80–82% Safety check on desaturation depth
Resting oxygen saturation ≥95% (conventional reference range) Baseline before a course
Resting blood pressure 90–120/60–80 mmHg Most frequently reported effect
Resting heart rate 60–100 beats/min Anchors the within-session ceiling
LDL cholesterol ≤4.2 mmol/L Fell over three-week courses
Total cholesterol, high-density lipoprotein and triglycerides Not specified in the ER Completes the lipid panel
Fasting glucose 3.9–5.5 mmol/L Fell in prediabetes and long COVID
Glycated haemoglobin Not specified in the ER Chronic blood-sugar picture
Haemoglobin and haematocrit Haemoglobin 13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women); haematocrit 38.8–50.0% (men), 34.9–44.5% (women) Safety check on red-cell stimulation
Alanine aminotransferase 10–49 U/L Liver enzymes fell in metabolic syndrome
Aspartate aminotransferase Not specified in the ER Paired with alanine aminotransferase
Kidney function Not specified in the ER Baseline before a course
Walking or step test Not specified in the ER Functional anchor for any gain

Cadence: Hypoxic pre-test and baseline panel before a course; saturation and pulse recorded continuously and symptoms scored every session; hypoxic test repeated after about three weeks; blood markers repeated two to three days after the final session, then at three to six months if a repeat course is considered

Qualitative Assessment

  • Headache, dizziness or nausea in the hours after a session, and whether these fade across the first three sessions
  • Perceived effort during the hypoxic phases
  • Breathlessness on exertion and everyday exercise tolerance
  • Fatigue through the day
  • Subjective mental clarity and recall
  • Sleep quality
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.